Posted by Michael Wonder on 25 Jul 2021
Highlights from the 19-22 July CHMP meeting
23 July 2021 - Two new medicines recommended for approval.
The CHMP adopted a positive opinion for Nexviadyme (avalglucosidase alfa), intended for the treatment of glycogen storage disease type II (Pompe disease).
